Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GBA1 | P04062 | 2/20 | 0.49 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4754607 | 0.90 | FUCA1 (0.54) | ALDH1A1GBA1FUCA1ACHESLC18A3 | |
| SCHEMBL7226848 | 0.84 | ALDH1A1 (0.55) | ALDH1A1GBA1FUCA1ACHESLC18A3 | |
| SCHEMBL7236741 | 0.82 | CCR3 (0.57) | ALDH1A1GBA1FUCA1ACHESLC18A3 | |
| SCHEMBL21593411 | 0.82 | GBA1 (0.66) | ALDH1A1GBA1FUCA1ACHESLC18A3 | |
| SCHEMBL1873794 | 0.82 | GBA1 (0.66) | ALDH1A1GBA1FUCA1ACHESLC18A3 | |
| SCHEMBL6042430 | 0.82 | GBA1 (0.66) | ALDH1A1GBA1FUCA1ACHESLC18A3 | |
| SCHEMBL21593408 | 0.82 | GBA1 (0.66) | ALDH1A1GBA1FUCA1ACHESLC18A3 | |
| SCHEMBL21593480 | 0.82 | GBA1 (0.66) | ALDH1A1GBA1FUCA1ACHESLC18A3 | |
| SCHEMBL7233965 | 0.82 | ALDH1A1 (0.52) | ALDH1A1GBA1FUCA1ACHESLC18A3 | |
| SCHEMBL3547837 | 0.81 | ALDH1A1 (0.55) | ALDH1A1GBA1FUCA1ACHESLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608078-B2 | Gramnegative bacteria | WOCKHARDT LIMITED (IN) | 2003-08-19 | — | — | US | disclosed |
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | WOCKHARDT RESEARCH CENTER | 2002-11-07 | — | — | US | disclosed |
| WO-2001085728-A2 | ANTIBACTERIAL CHIRAL 8-(SUBSTITUTED PIPERIDINO)-BENZO [I, J] QUINOLIZINES, PROCESSES, COMPOSITIONS AND METHODS OF TREATMENT | WOCKHARDT LIMITED (IN) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | ALPI, POLR1C, POLI | ALDH1A1 2656/4885GBA1 866/4885FUCA1 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.